Ładuje się......
Relationship between adverse events associated with lenvatinib treatment for thyroid cancer and patient prognosis
Tyrosine kinase inhibitors (TKIs) were first approved for treating radioactive iodine-refractory differentiated thyroid cancer (DTC) and anaplastic thyroid cancer (ATC) 5 years ago. Among them, lenvatinib has a high response rate and has become the first-line drug for treating thyroid cancer. Althou...
Zapisane w:
| Wydane w: | Mol Clin Oncol |
|---|---|
| Główni autorzy: | , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
D.A. Spandidos
2021
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7783723/ https://ncbi.nlm.nih.gov/pubmed/33414909 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2020.2190 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|